Elektra Health, a femtech startup based in NYC, has completed its seed fundraising with a $3.75 million capital raise.
The seed round was co-led by Alexis Ohanian’s Seven Seven Six and Flare Capital Partners. Other investors include City Light Capital, Human Ventures, January Ventures, The Fund, Community Fund, Claire Diaz-Ortiz, Hannah & Guy Raz, and Jenny Fielding.
With the new funds, the NYC-based company is planning to expand its services, including integrative and evidence-based solutions, for millions of women in the U.S. as well as strengthen and develop its team.
Founded by Alessandra Henderson and Jannine Versi, Elektra Health develops a health platform for millions of women in the U.S. navigating menopause. It uses evidence-based education, virtual care, and community programming via its proprietary “Meno-morphosis” program.
“We are all about caring for women by providing content, education, care, coaching, and counseling, especially working in the arc of their journey,” Versi, Co-Founder & Chief Operating Officer at Elektra Health continued, “This is such an intimate topic, but we have referral rates of 40% where women are talking about it themselves and then bring a friend along. Sustaining that is important to us. We are seeing clusters of friends come along and really bond with the community.”
Menopause is a hormonal health transition that women will typically go into when they are in their 40s or 50s. According to research, there have been up to 34 identified symptoms of menopause.
While 80% of women say menopause symptoms have negatively impacted their quality of life in some way, less than 20% of obstetrics/gynecology residency programs educate doctors about menopause.
The Elektra Health program features evidence-based pathways for managing symptoms, as well as community cohort support and 1:1 access to a dedicated menopause expert to solve those problems.
To date, Elektra’s programming has attracted over 1,800 participants. It is currently in private beta but will open completely to the public in 2022.